
ZURA Stock Forecast & Price Target
ZURA Analyst Ratings
Bulls say
Zura Bio is a Henderson, NV based, clinical-stage biopharmaceutical company, with their leading candidate tibulizumab showing positive results in its Phase 2 TibuSHIELD study for the treatment of hidradenitis suppurativa (HS). With a strong cash position and ongoing development in systemic sclerosis (SSc), Zura has an attractive risk/reward setup, but faces potential challenges in market competition and intellectual property risks. So while regulatory and commercial risks may inhibit approval and market penetration, positive results for tibulizumab and ongoing developments make Zura Bio's stock a promising investment.
Bears say
Zura Bio is a clinical-stage biotech company based in San Diego. With a focus on immunology and the development of novel medicines for patients with autoimmune and inflammatory diseases, their three in-licensed clinical-stage product candidates – Tibulizumab (ZB-106), Crebankitug (ZB-168), and Torudokimab (ZB-880) – aim to address serious and debilitating conditions with unmet medical need. However, their reliance on external funding and potential challenges in clinical development, regulatory approvals, and commercialization pose significant risks to the company's attainment of its projected operational runway and potential market success.
This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ZURA Analyst Forecast & Price Prediction
Start investing in ZURA
Order type
Buy in
Order amount
Est. shares
0 shares